BOSTON – June 3, 2025 – Biotech firm Bicara Therapeutics (represented by the ticker BCAX) is gearing up for a spotlight at the Goldman Sachs 46th Annual Global Healthcare Conference. Management will be participating in a fireside chat this Tuesday, June 10th, at 3:20 p.m. ET, offering investors a chance to gain deeper insights into the company’s strategy and pipeline.
The presentation will be streamed live via webcast, accessible through the Investor Relations section of their website, under “Events and Presentations.” For those unable to tune in live, a replay of the webcast will also be made available shortly after the event concludes.
About Bicara Therapeutics
Bicara Therapeutics is entering the clinical-stage with the intent of revolutionizing the treatment landscape for solid tumors through its bifunctional therapies. The company’s lead program, ficerafusp alfa, is a novel, first-in-class bifunctional antibody. Its design aims to overcome barriers within the tumor microenvironment, which have historically complicated treatment of multiple solid tumor cancers. The therapy marries two clinically validated targets: an epidermal growth factor receptor (EGFR)-directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). This targeted mechanism works to counter the fibrotic and immune-excluded environment that often characterizes tumors, thereby enabling deeper and more lasting responses. The company is initially focusing ficerafusp alfa’s development on head and neck squamous cell carcinoma, where it sees a significant unmet need, and is also exploring its potential in other solid tumor types.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/1661.html
